EpiPen CEO claims profit is small — despite $11B in sales
Mylan Chief Executive Heather Bresch insists the pharma giant isn’t making a killing off its life-saving EpiPen. Bresch told lawmakers on Wednesday that — despite a six-fold increase in the price over the past nine years — the emergency allergy shot isn’t as profitable as people think. The EpiPen has gone from $100 for a...
No comments